Grace Therapeutics, Inc. Common Stock (GRCE) Stock Price

GRCEStock

$2.20−32.92%52W

Market Cap$46.28M

P/E—

PEG Ratio—

Div yield—

Beta0.31

GRCE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.06%

Price vs S&P 500 (4W)-6.16%

VGM Score39.29

Book Value / Share (Quarterly)$3.99

P/TBV (Annual)3.15x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.44

Price vs S&P 500 (YTD)-48.95%

Gross Margin (TTM)65.00%

Net Profit Margin (TTM)-4435.00%

EPS (TTM)$-0.47

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-0.47

EPS (Annual)$-1.35

ROI (Annual)-20.82%

Gross Margin (Annual)60.00%

Net Profit Margin (5Y Avg)-5595.44%

Cash / Share (Quarterly)$1.06

ROA (Last FY)-17.53%

EBITD / Share (TTM)$-0.67

ROE (5Y Avg)-64.77%

Operating Margin (TTM)-2130.00%

Cash Flow / Share (Annual)$-0.55

P/B Ratio0.53x

P/B Ratio (Quarterly)1.12x

Net Income / Employee (Annual)$-401,700

Net Interest Coverage (TTM)-7.01x

ROA (TTM)-6.59%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)8.10x

Quick Ratio (Quarterly)7.92x

3-Month Avg Trading Volume0.44M

52-Week Price Return-32.92%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.42

P/S Ratio (Annual)168.44x

Asset Turnover (Annual)0.00x

52-Week High$5.18

Operating Margin (5Y Avg)-5314.69%

EPS Excl Extra (Annual)$-1.35

26-Week Price Return-44.81%

Quick Ratio (Annual)7.92x

13-Week Price Return-2.68%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.10x

Enterprise Value$16.71M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.40x

Pretax Margin (Annual)-9840.00%

Cash / Share (Annual)$1.06

3-Month Return Std Dev49.33%

Gross Margin (5Y Avg)67.56%

Net Income / Employee (TTM)$-243,500

ROE (Last FY)-20.82%

Net Interest Coverage (Annual)-5.12x

EPS Basic Excl Extra (Annual)$-1.35

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.47

Receivables Turnover (Annual)1.60x

ROI (TTM)-6.94%

P/S Ratio (TTM)168.44x

Pretax Margin (5Y Avg)-5595.44%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.42

Price vs S&P 500 (52W)-51.23%

Year-to-Date Return-36.99%

5-Day Price Return2.35%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-44.34%

Net Profit Margin (Annual)-9840.00%

Month-to-Date Return4.81%

EBITD / Share (Annual)$-1.34

Operating Margin (Annual)-8210.00%

LT Debt / Equity (Annual)0.20x

ROI (5Y Avg)-64.77%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.47

P/TBV (Quarterly)3.15x

P/B Ratio (Annual)1.12x

Inventory Turnover (TTM)1.00x

Pretax Margin (TTM)-4435.00%

Book Value / Share (Annual)$3.99

Price vs S&P 500 (13W)-5.47%

Beta0.31x

Revenue / Share (TTM)$0.00

ROE (TTM)-6.94%

52-Week Low$1.79

mGradeD

vgmGradeD

GRCE Earnings Surprise History

Q2 25-0.29est. -0.31

Q3 25-0.08est. -0.34

Q4 25-0.19est. -0.39

Q1 26-0.08est. -0.20

Q2 26-0.18est. -0.18

GRCE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
GRCEGrace Therapeutics, Inc. Common Stock	—	—	D	$2.20
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Grace Therapeutics, Inc. Common Stock

Grace Therapeutics is a specialty pharmaceutical company developing drug delivery technologies for rare and orphan diseases. Its lead program, GTx-104, is a novel injectable nimodipine formulation in late-stage development for aneurysmal subarachnoid hemorrhage. The company's pipeline includes additional candidates targeting ataxia-telangiectasia, postherpetic neuralgia, and other rare disease indications.